Perkin-Elmer acquisition of PerSeptive Biosystems beefs up PE's protein analysis service offerings.
PERKIN-ELMER ACQUISITION OF PERSEPTIVE BIOSYSTEMS ADDS PROTEIN ANALYSIS technology to Perkin Elmer's line of DNA sequencing technologies, broadening its technology platform for drug discovery and biomedical research. PE announced a definitive stock-swap agreement to purchase Framingham, Mass.-based PerSeptive on Aug. 25. The deal is expected to close by year end.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth